98%
921
2 minutes
20
Lupin is a high-protein legume crop that grows in a wide range of edaphoclimatic conditions where other crops are not viable. Its unique seed nutrient profile can promote health benefits, and it has been proposed as a phytoremediation plant. Most rhizobia nodulating species belong to the genus comprising strains that are phylogenetically related to , and . Lupins are also nodulated by fast-growing bacteria within the genera , , , , and . Phylogenetic analyses of the and genes, involved in microbial colonization and symbiotic nitrogen fixation, respectively, suggest that fast-growing lupin-nodulating bacteria have acquired their symbiotic genes from rhizobial genera other than . Horizontal transfer represents a key mechanism allowing lupin to form symbioses with bacteria that were previously considered as non-symbiotic or unable to nodulate lupin, which might favor lupin's adaptation to specific habitats. The characterization of yet-unstudied species, including microsymbiont whole genome analyses, will most likely expand and modify the current lupin microsymbiont taxonomy, and provide additional knowledge that might help to further increase lupin's adaptability to marginal soils and climates.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094711 | PMC |
http://dx.doi.org/10.3390/ijms24076496 | DOI Listing |
J Immunother Precis Oncol
August 2025
The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.
Introduction: Patients with advanced solid tumors may be considered for early phase clinical trials investigating the safety, tolerability, and dosing of experimental therapies. Optimizing participant selection is critical to maximize clinical benefit and meet trial endpoints with fewer participants. One in six participants does not meet routine life expectancy requirements (>3 months), highlighting the need for improved prognostication.
View Article and Find Full Text PDFJACC Heart Fail
September 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Department of Internal Medicine, School of Clinical Medicine, Hangzhou Normal University, Hangzhou, China. Electronic address:
Compr Rev Food Sci Food Saf
September 2025
School of Molecular and Life Sciences, Faculty of Science and Engineering, Curtin University, Bentley, Western Australia, Australia.
Introducing underutilized legumes as plant-based protein sources to daily meals is an approach to address the increasing demand for alternative proteins. However, legumes often exhibit off-flavors and aromas, causing negative consumer perceptions. Lupins are an underutilized legume that is becoming popular as a plant protein source due to their high protein, fiber, and low starch contents.
View Article and Find Full Text PDFCochrane Database Syst Rev
September 2025
Division of Gastroenterology, Hepatology, and Nutrition, SickKids Research Institute and SickKids Learning Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
Background: Training in endoscopy has traditionally been based upon an apprenticeship model, where novices develop their skills on real patients under the supervision of experienced endoscopists. In an effort to prioritise patient safety, simulation training has emerged as a means to allow novices to practice in a risk-free environment. This is the second update of the review, which was first published in 2012 and updated in 2018.
View Article and Find Full Text PDFRespir Med
September 2025
Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom. Electronic address:
Background: Eosinophilic chronic obstructive pulmonary disease (eCOPD), characterized by type 2 inflammation, is an emerging target for biologic therapies.
Objective: To indirectly compare the efficacy of dupilumab and mepolizumab in eCOPD, defined as blood eosinophil counts ≥300 cells/μL, by synthesizing data from phase 3 randomized controlled trials: BOREAS and NOTUS for dupilumab, MATINEE for mepolizumab.
Methods: We performed an indirect comparison of trial primary and secondary outcomes including annual exacerbation rates (AER), quality of life (St.